Atu-614

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameAtu-614
Drug Alias NameDBTC programs (Silence Therapeutics)
ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApoptosis-mediating surface antigen FAS inhibitors
TargetsApoptosis-mediating surface antigen FAS
Therapy Area/IndicationsLiver Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSilence Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSilence Therapeutics Plc
Active IndicationsN/A
Inactive IndicationsLiver Failure

Other Information

ATC CodeN/A
Related LinksN/A